5-(2-Fluorophenyl)-N-Methyl-1-(3-Pyridinylsulfonyl)-1H-Pyrrole-3-Methanamine (2E)-2-Butenedioate

For direct compression of vonoprazan fumarate immediate-release tablets carrying a low unit dose of the base equivalent—either 10 mg or 20 mg—the prevailing technical challenge is not the chemical stability of the sulfonyl pyrrole salt but the physical dispersion of an API whose agglomerated primary particles frequently exhibit a D₉₀ exceeding 35 μm. To meet the acceptance criteria for content uniformity laid out in USP <905> (Uniformity of Dosage Units) and the Japanese Pharmacopoeia JP 18 general test chapter <6.02>, a pre-blending sequence is executed in a 300 L to 1200 L bin blender of the Bohle or Matcon design, operated at 8 rpm to 12 rpm for 400 to 600 revolutions. The API is geometrically diluted with a portion of microcrystalline cellulose PH‑102 (50–60% w/w of the total formulation) and spray-dried lactose monohydrate (20–28% w/w) prior to main blending. The addition ratio of vonoprazan fumarate in the final blend typically occupies 10% to 14% w/w for the 20 mg strength and 5% to 8% w/w for the 10 mg strength, with crospovidone (Type A, 4–6% w/w) used as a superdisintegrant to achieve disintegration times below 120 seconds in 0.1 M HCl at 37 ± 0.5 °C. Once the pre-blend moves past the intermediate bulk container stage, magnesium stearate (vegetable grade, 0.75–1.0% w/w) is introduced through a 500 μm mesh and mixed for precisely 3–4 minutes; any extension beyond 5 minutes at 12 rpm raises the specific surface area coverage of the lubricant platelet network, resulting in a measurable decline in tensile strength and a delay in dissolution onset. Downstream compression is performed on a Korsch XL 400 or Fette 3090i rotary press fitted with 8 mm round, concave, bevel-edged tooling and a three-paddle force feeder running at 15–25 rpm. Target compaction force is held between 8 kN and 14 kN, producing tablets with a hardness of 55 N to 80 N and a friability consistently below 0.4% when tested per USP <1216>. The core tablets are then film-coated in a fully perforated drum coater (Glatt GC 750) applying an aqueous Opadry® AMB suspension at a spray rate of 180 g/min/barrel to achieve a 3.0–4.0% weight gain, with inlet air temperature 65–70 °C and exhaust humidity monitored below 12 g/kg. The terminal dosage form is a light-pink, circular, biconvex film-coated tablet packaged in Aclar/PVC blister cavities with aluminium foil lidding, and compliance is anchored to ICH Q3B(R2) impurity thresholds (reporting threshold 0.1%, identification threshold 0.2%), the dissolution specification NLT 80% (Q) in 30 min using Apparatus 2 at 50 rpm in 900 mL 0.1 M HCl as prescribed by JP <6.10>, and full adherence to manufacturing environment class 100,000 per 21 CFR 211. Experience on commercial lines indicates that when the ambient RH creeps above 60% during hopper discharge, the equilibrium moisture content of the fumarate salt can drift toward 2.5–3.0%, triggering marginal hydrate species formation detectable by differential scanning calorimetry; in such cases, dry-air purging of the feed frame at a dew point of −40 °C becomes mandatory to preserve the tablet stability profile and avoid out-of-specification results for dissolution after 6-month accelerated storage at 40 °C/75% RH.

Why wet-granulation remains the preferred route for vonoprazan fumarate oral solid dosage manufacture when downstream unit-dose sachet filling demands fluidized-bed intermediate processing?

When the production target shifts from single-entity tablets to granulated intermediates destined for stick-pack or unit-dose sachet filling—often dictated by paediatric, geriatric, or dysphagia patient requirements—a high-shear wet-granulation workflow offers superior particle size distribution control and eliminates the segregation hazard inherent to low-dose direct-compression blends. The API is first geometrically diluted with milled mannitol (Pearlitol 200SD) and hypromellose (Pharmacoat 606) to generate a pre-mix comprising 2.5–4.0% w/w vonoprazan fumarate, corresponding to 10 mg of the base per 500 mg sachet fill weight. This pre-mix is transferred into a GEA Pharma Ultima Pro 150 high-shear mixer-granulator, where the binder solution—purified water containing 5% w/w copovidone (Plasdone S‑630) and 0.8% w/w sucralose as a taste-masking co-solute—is spray-injected at a mass flow of 2.0 kg/min while the main impeller operates at 120 rpm and the chopper at 1800 rpm. Granulation endpoint is controlled not by subjective visual cues but by batch-recorded power consumption trending; the process is terminated when the impeller torque stabilizes in a corridor of 18 N·m to 22 N·m after a wet massing interval of 90–120 seconds. The wet granules are discharged through a 2.0 mm Quadro Comil screen and immediately dried in a Glatt GPCG 60 fluid-bed dryer with an inlet air temperature of 55 °C, bed product temperature ceiling of 38 °C, and an end-point loss-on-drying target of 1.5–2.0%. Dry granules are milled again through a 0.8 mm screen and blended with silicon dioxide (Syloid 244 FP, 0.5% w/w) and magnesium stearate (0.5% w/w) in an 800 L bin blender for 200 revolutions. The resulting free-flowing granules exhibit a Carr’s compressibility index below 15% and are filled on a Höfliger & Karg sachet machine at a throughput of 200–250 units/min. The terminal dosage form is a 500 mg flavoured powder for oral suspension, placed in a laminate sachet of PET/Al/PE, and the compliance framework incorporates JP 18 General Rules for Preparations, ICH Q6A decision tree #8 for particle size distribution, and USP <1102> for dose-delivery accuracy of sachet presentations. A documented process limitation emerges when starch 1500 is used as a diluent: at filler loadings exceeding 15% w/w, the granules develop a tenacious agglomeration capacity under accelerated conditions of 40 °C/75% RH, increasing disintegration time beyond the 3-minute paediatric specification limit.

Vonoprazan dry syrup microsphere layering and organoleptic masking strategies under JP paediatric formulation requirements

Production of a ready-to-reconstitute dry syrup intended for weight-based dosing in paediatric acid-related disorders requires not only a narrow particle size span for dose uniformity but also a multi-layer barrier coating that suppresses the intense bitter taste of the phenyl-pyrrole sulfonamide core without compromising immediate dissolution in the stomach at pH 1.2. The manufacturing campaign starts with commercially sourced vonoprazan fumarate that has been jet-milled to a volume median diameter (D₅₀) of 2.5 μm to 4.0 μm to ensure that the drug content per microsphere does not exceed 0.8% w/w. A fluidized Wurster bottom-spray coater (Glatt GPCG 3.1 equipped with a 6-inch Wurster insert) applies three sequential layers onto sucrose spheres (Suglets® 500–600 μm): first, a drug-layering suspension composed of the micronized API, hypromellose 2910 (5% w/v as binder), and mannitol in a 1:8 ratio, sprayed at 8 g/min with an atomizing air pressure of 1.8 bar until a drug load of 0.75% w/w is achieved; second, a sub-coat of 4% w/w Eudragit® E PO dissolved in an acetone‑water mixture, which precipitates a pH-dependent taste-masking shell that remains intact at saliva pH 7.4 but ionizes and dissolves within 90 seconds upon contact with gastric fluid; third, an over-coat of mannitol and colloidal silica (Aerosil 200, 1.5% w/w) to prevent electrostatic clumping during sachet filling. After sieving through a 1000 μm security screen, the finished microspheres are blended with saccharin sodium (0.2% w/w) and a strawberry flavour granulate (0.5% w/w) in a low-shear tumbler. The resulting intermediate is filled into aluminium-foil laminated stick-packs under N₂ flush to maintain headspace oxygen below 2% v/v. The terminal dosage form is a 1.0 g dry syrup powder for suspension, delivering 2 mg of vonoprazan per kg body weight when reconstituted with 10 mL potable water. Quality release criteria follow JP 18 <6.02> mass variation testing for divided powders, dissolution apparatus 4 (flow-through cell) at 16 mL/min in 0.1 M HCl with a sampling point of 30 min and Q = 80%, and the formulation is evaluated for extractable leachables from the polyethylene-laminate packaging per ICH Q3D Elemental Impurities risk assessment. An operational boundary of this wet-coating process lies in the dependency on the acetone residual content: if the sub-coat drying temperature deviates below 45 °C for more than 15 minutes during the ramp-down phase, residual acetone levels exceed the 5000 ppm limit prescribed by ICH Q3C Class 3 solvent guideline, necessitating an additional 48-hour tray-drying step that compromises the microsphere integrity and leads to burst release in the first 10 minutes of dissolution.

No single application of vonoprazan fumarate in analytical laboratory infrastructure generates higher regulatory scrutiny than the preparation and certification of a Pharmacopoeia-grade Reference Standard intended for identity, assay purity, and chromatographic system suitability testing. While the active substance is manufactured under ICH Q7 GMP, the step-up to a Certified Reference Material (CRM) that meets the metrological traceability requirements of ISO 17034:2016 demands a separate purification scheme uncoupled from the production-scale batch records. The starting batch—pre-screened by HPLC to contain no single impurity above 0.15% area—is dissolved in a heated mixture of anhydrous ethanol and water (1:2.5 v/v) at 60 °C, and the solution is polish-filtered through a 0.22 μm PVDF membrane to remove insoluble particulate matter. The crystallization is conducted in a stirred jacketed vessel of 20 L working volume with the temperature linearly ramped down from 60 °C to 5 °C over 8 hours under slow agitation (60 rpm, retreat-curve impeller). The harvested crystals are washed with chilled 2 °C acetone and vacuum-dried in a Büchi B‑290 oven at 38 °C and 10 mbar for 24 hours to reach a residual solvent content below the 0.5% threshold. A second recrystallization under identical solvent ratio—now adjusted to 1:3 v/v to increase the yield of the low-solubility fumarate salt—further reduces the total related substances to below 0.05% as determined by a validated UPLC method using a sub‑2 μm C18 column and detection at 230 nm. The terminal product is a white to off-white crystalline powder subdivided into amber-glass vials under argon atmosphere, each containing 50 mg of the standard. This powder serves as the primary reference standard in the calibration of quantitative HPLC assays, as the system suitability test compound for the USP <621> chromatographic procedure, and as the traceable anchor for the content uniformity testing of finished tablets. The certification protocol integrates JP 18 Reference Standard lot release criteria, USP <11> collaborative study guidelines, and the extended mass balance approach described in WHO Technical Report Series 943. For this specific high-purity application, the addition ratios of the recrystallization solvents must be strictly clamped; a deviation of the ethanol‑water ratio to 1:2 results in a supersaturation burst that fosters the nucleation of a kinetically trapped polymorphic form, manifesting as a melting point depression of 3–5 °C and a crystalline-lattice fourier transform infrared spectral shift at 1685 cm⁻¹ that invalidates the reference standard lot versus the official JP standard.

When combination therapy kits require accelerated stability monitoring under ICH Zone IVb conditions for H. pylori triple eradication blister assembly

Commercialisation of the first-line vonoprazan-based Helicobacter pylori eradication regimen relies not on a co-formulated tablet but on a paperboard‑ or PVC‑overwrapped kit containing one vonoprazan 20 mg film-coated tablet, one amoxicillin 750 mg capsule, and one clarithromycin 200 mg tablet, all positioned in a single push-through aluminium blister sheet. The primary manufacturing step that concerns the vonoprazan component is the long-term physical and chemical compatibility study conducted under ICH Q1A(R2) conditions for Zone IVb (30 °C/75% RH long-term and 40 °C/75% RH intermediate). While the vonoprazan tablet is produced under a standalone direct-compression or granulation route with an API load of 12–14% w/w and magnesium stearate limited to 0.8% w/w, the placement of the tablet in a shared cavity with an amoxicillin capsule—which holds a moisture-vulnerable sodium amoxicillin trihydrate fill—demands a blister packaging configuration that suppresses inter-drug moisture migration. The selected cold-form laminate has a thickness gradient of 25 μm OPA/45 μm Al/60 μm PVC, and blister pockets are filled in a Marchesini MB 451 blister line under a dry nitrogen atmosphere maintaining a dew point below −30 °C and an operational ambient RH of less than 25%. In-process controls include a daily leak test using a Seidenader visual inspection system and a bulk desiccant packet (silica gel 5 g) inserted into the secondary pouch before heat-sealing. Stability-indicating method validation focuses on the quantitation of potentially migrating volatile amine impurities that could generate vonoprazan degradation product D (N‑desmethyl impurity, relative retention time 0.62) and is calibrated against the acceptance criterion of 0.2% maximum allowed for any unspecified degradation product as per ICH Q3B(R2). After 6 months at 40 °C/75% RH, vonoprazan tablets remaining under 98.5% of label potency and showing no dissolution shift greater than 10% compared to initial time point are deemed compliant. The terminal dosage form is a sealed composite blister strip holding the three drug forms, serialized via an in‑line coding camera and bundled into a patient leaflet carton with holo‑laminate tamper‑evidence. A distinct technical boundary governs the clarithromycin component: any interaction between the clarithromycin crystalline pre-formulation (which has a pH-dependent surface hydration) and the sulfonyl pyrrole ring of vonoprazan can be triggered during geographical transport above 45 °C, leading to a minor cross-interference adduct; therefore, the blister design incorporates a 5 mm intra-cavity separation ridge to prevent direct physical contact between the tablet surface and the capsule shell throughout the entire supply chain.

High-shear feeder over-lubrication of direct-compression blends on rotary presses: processing window limits and dissolution failure modes

Perhaps no manufacturing variable generates sharper dissolution cliff-edges in low-dose vonoprazan fumarate tablet production than the interaction between rotary press forced-feeder design parameters and the mixing-sensitive lubricant magnesium stearate. Pilot‑ and commercial‑scale data gathered from Korsch XL 400 presses synchronized with K‑TRON T 35 loss‑in‑weight feeders have demonstrated that when the feeder paddle rotational speed exceeds 22 rpm for an extended run of over 70,000 compression events, the cumulative shear energy imparted to the powder bed distributes the pre‑blended magnesium stearate (0.9–1.1% w/w) into a thin hydrophobic film whose fractal platelets align on the surface of the larger microcrystalline cellulose particles. This condition—termed “over‑lubrication stratification”—is not detectable by routine hardness testing because tablet breaking force often remains within the 55 N–75 N corridor, but it manifests as a pronounced reduction in the dissolution rate slope between the 5‑minute and 20‑minute sampling points. Under USP <711> Apparatus 2 monitoring at 50 rpm in 0.1 M HCl, tablets manufactured from blends that have been subjected to feeder residence times above 8 minutes while the paddle motor is energised can exhibit percentage dissolved values as low as 52% at 15 minutes, compared with a control lot released at 88%. The root cause has been traced through SEM imaging of fractured tablet cores, which reveals a continuous lubricant domain on MCC platelet edges rather than a discrete particle-boundary distribution. The operational countermeasure, validated per ASTM E2363 rheological mixing profiles, mandates that the final lubricated blend remain inside the feed frame for no more than 5 minutes, and that mobile blending of the bulk IBC be performed immediately before discharging into the press hopper. Additionally, the lubricant itself is restricted to a vegetable-sourced magnesium stearate with a specific surface area of ≤ 3 m²/g (e.g., Peter Greven Ligamed MF‑2‑V) to reduce film-formation kinetics. The overriding compliance framework for this process scrutiny is anchored to FDA SUPAC‑IR guidance (change in manufacturing equipment of the same design and operating principle) and the ASTM E2709 standard practice for batch acceptance using acceptance limit tables. The terminal dosage form is the 10 mg or 20 mg immediate-release film-coated tablet described in earlier sections, but its batch record now incorporates a forced‑feeder load-cell monitoring step that triggers an alarm if the paddle motor torque deviates by more than ±15% from the qualification-run baselines. A hard chemical incompatibility boundary has been established: co‑processing this API with amberlite‑based ion‑exchange resin (Polacrilex) in an attempt to coat the particle for taste masking is strictly inadvisable at lubricant levels above 0.5% because the sulfonic acid groups catalyze the hydrolytic opening of the pyrrole ring when the lubricant film synergistically prevents moisture egress, yielding an unacceptably high concentration of the des‑sulfonyl degradant (RRF 1.8) within 3 weeks under 40 °C/75% RH stress.